Drugs / racemic albuterol
last change Feb 2006 re-read 9 days ago

racemic albuterol

Developed for
asthma · acute asthma · exercise-induced bronchoconstriction · status asthmaticus
Investigated by
Sumitomo Pharma America, Inc.

Trials 2

2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT00684866 Jan → Jul 2003 asthma Sumitomo Pharma America, Inc. Completed No outcome recorded
Phase 31 trial
Phase 3 NCT00073840 Dec 2002 → Jun 2003 asthma Sumitomo Pharma America, Inc. Completed No outcome recorded
Comparator or background therapy10 trials
Phase 2 NCT00685022 Comparator Jun → Aug 2003 asthma Sumitomo Pharma America, Inc. Completed No outcome recorded
Phase 2 NCT00685347 Comparator Jan → Jun 2003 exercise-induced bronchoconstriction Sumitomo Pharma America, Inc. Completed No outcome recorded
Phase 2 NCT00684827 Comparator Oct 2002 → Feb 2003 asthma Sumitomo Pharma America, Inc. Completed No outcome recorded
Phase 2 NCT01656811 Comparator Oct 2001 → Jul 2002 asthma Sumitomo Pharma America, Inc. Completed No outcome recorded
Phase 3 NCT00064389 Comparator Jan 2003 → Jul 2005 asthma Sumitomo Pharma America, Inc. Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as racemic albuterol “* Racemic Albuterol 180 ųg QID” NCT00073840 ↗
11

NCT01656811 ↗

NCT00064389 ↗

NCT00685347 ↗

NCT00667407 ↗

NCT00685022 ↗

NCT00073814 ↗

NCT00124176 ↗

NCT00685425 ↗

NCT00684827 ↗

NCT00073827 ↗

Show 1 more source

Known as R+S albuterol “Racemic albuterol (R+S albuterol)” NCT00124176 ↗
Known as Racemic Albuterol Sulfate “Drug: Racemic Albuterol Sulfate” NCT00667407 ↗
Route Inhaled “racemic albuterol HFA MDI 180 mcg QID” NCT00064389 ↗